Delivery Order SPE2DB24D1201-SPE2DB25FJDZE
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Vyvanse 30 mg capsules (100-count units) at a ceiling value of $5,051.16. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is set for ultimate completion by August 6, 2025, and will be fulfilled from the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Vyvanse 40 mg capsules (100-count units) at a ceiling value of $1,665.22. This firm fixed-price delivery order, with an ultimate completion date of August 19, 2025, represents a competitive award with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Vyvanse 50 mg capsules (100-count units) with a ceiling value of $2,917.37 and a completion date of August 11, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and will be performed at the contractor's Conshohocken, Pennsylvania location. The award is executed as a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 30 mg capsules (100 count) under a firm fixed-price contract with a ceiling value of $1,918.73. The award, issued on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Vyvanse 20 mg capsules (100-count units) under a firm fixed-price contract valued at $6,292.03. The order, which is not set-aside for any disadvantaged business category, is scheduled for completion by August 13, 2025, and will be performed at the vendor's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $1,241.46 to AmerisourceBergen Drug Corp for Vyvanse 40 mg capsules (100-count) on July 24, 2025, with an ultimate completion date of July 25, 2025. This firm fixed-price contract represents a competitively awarded, non-set-aside delivery order for pharmaceutical supply to support federal medical procurement needs. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $2,258.69 on August 18, 2025, for the supply of Vyvanse 20 mg capsules (100-count units). This non-competitive, firm fixed-price delivery order is scheduled for completion by August 19, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Vyvanse 50 mg capsules (100-count) under a firm fixed-price contract with a ceiling value of $5,192.54. The order, which is classified as a child contract under a larger indefinite delivery vehicle, carries an ultimate completion date of July 24, 2025. This delivery order was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's capability to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Vyvanse 60 mg capsules (100-count units) with a contract ceiling value of $1,378.96. This is a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Vyvanse 30 mg capsules (100-count units) at a ceiling value of $2,079.25. This is a firm fixed-price delivery order with an ultimate completion date of July 28, 2025. The award represents a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends...
- SPE2DB24D1201Indefinite Delivery Contract
- SPE2DB24D1201-SPE2DB25FJDZEDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Vyvanse 10 mg capsules in quantities of 100 units. This is a firm fixed price delivery order with a ceiling value of $1,933.29 and an ultimate completion date of August 21, 2025. The contract involves no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform the delivery from its corporate office location at the same address. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999.9 million through December 2026. This prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. The delivery of Vyvanse, a prescription stimulant medication used primarily for attention-deficit/hyperactivity disorder treatment, represents a routine pharmaceutical resupply transaction supporting the Defense Health Agency and other federal healthcare systems through this flexible contracting vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 8/20/25 |